News
HCM
14.66
+6.62%
0.91
Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Here's What You Should Know
NASDAQ · 19h ago
Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026
Benzinga · 20h ago
HUTCHMED's ESLIM-02 Trial Of Sovleplenib In Warm Autoimmune Hemolytic Anemia Meets Key Goal
NASDAQ · 1d ago
Reported Earlier, HUTCHMED Announces Phase III ESLIM-02 Trial Success For Sovleplenib Expanding Immunology And Hematology Pipeline
Benzinga · 1d ago
HUTCHMED's Sovleplenib Reaches Phase III Goal In Warm Autoimmune Hemolytic Anemia Trial In China
NASDAQ · 1d ago
Hutchmed says Phase III of ESLIM-02 trial met primary endpoint
TipRanks · 1d ago
BRIEF-Hutchmed Announces Positive Topline Phase III Trial Of Sovleplenib For Warm Antibody Autoimmune Hemolytic Anemia
Reuters · 1d ago
HUTCHMED Reports Positive Phase III Results for Sovleplenib in wAIHA Trial
Reuters · 1d ago
HUTCHMED (CHINA) LTD - PHASE III TRIAL OF SOVLEPLENIB MEETS PRIMARY ENDPOINT
Reuters · 1d ago
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Barchart · 1d ago
Hutchmed price target lowered to $22 from $25 at BofA
TipRanks · 1d ago
Bank of America Securities Keeps Their Buy Rating on HUTCHMED (HCM)
TipRanks · 1d ago
Sony Honda Mobility Unveils New Afeela Prototype As CEO Mizuno Expects Afeela 1 Deliveries In California Late 2026 And Japan In H1 2027 With New Model Targeted For US By 2028
Benzinga · 2d ago
HUTCHMED Begins Phase 3 Part Of Phase 2/3 Surufatinib-Camrelizumab Combo Study In Pancreatic Cancer
NASDAQ · 3d ago
Weekly Report: what happened at HCM last week (1229-0102)?
Weekly Report · 3d ago
Hutchmed initiates Phase III stage of Phase II/III trial
TipRanks · 3d ago
HUTCHMED Launches Phase III Trial of Surufatinib and Camrelizumab Combo for Metastatic Pancreatic Cancer
Reuters · 3d ago
HUTCHMED INITIATES PHASE III STAGE OF THE ONGOING TRIAL OF THE COMBINATION OF SURUFATINIB AND CAMRELIZUMAB FOR TREATMENT-NAÏVE PANCREATIC DUCTAL ADENOCARCINOMA
Reuters · 3d ago
HUTCHMED Announces NDA Acceptance In China For Savolitinib In MET-Amplified Gastric Cancer
NASDAQ · 12/30/2025 14:49
Hutchmed announces savolitinib new drug application acceptance in China
TipRanks · 12/30/2025 10:10
More
Webull provides a variety of real-time HCM stock news. You can receive the latest news about Hutchmed (China) Limited through multiple platforms. This information may help you make smarter investment decisions.
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.